TG Therapeutics Inc (TGTX) stock news · P/E 20, rev $616.3M
TG Therapeutics Inc (TGTX) is a biotechnology company listed on NASDAQ.
This TGTX news page leads with what TG Therapeutics Inc filed — not a scraped headline mill.
No cached 8-K sentence for TGTX yet. We will not pad this page with generic market recap.
Latest reported TGTX revenue for 2025-12-31 was $616.3M. Net income was $447.2M. Revenue was up 87.3% from 2024-12-31 to 2025-12-31. TGTX currently screens at market cap $7.88B and trailing P/E 19.7.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the TGTX stock page; for the tape open the quote page.
TGTX stock news FAQ
What are TGTX's latest revenue and net income?
Latest cached TG Therapeutics Inc (TGTX) revenue for Dec 31, 2025 was $616.3M. Net income was $447.2M. Statements: https://lician.com/financials/tgtx
How did TGTX revenue change from the prior cached period?
Cached TG Therapeutics Inc (TGTX) revenue was up 87.3% from $329.0M (Dec 31, 2024) to $616.3M (Dec 31, 2025). Statements: https://lician.com/financials/tgtx
What is TGTX's P/E ratio?
TG Therapeutics Inc (TGTX) trailing P/E is 19.7 on the latest cached fundamentals snapshot.
What is TGTX's market cap?
TG Therapeutics Inc (TGTX) market cap is $7.88B on the latest cached fundamentals snapshot.
What kind of company is TGTX?
TG Therapeutics Inc (TGTX) is a biotechnology company listed on NASDAQ.
Where is TGTX stock news listed?
Cached stock news for TG Therapeutics Inc (TGTX) is listed at https://lician.com/news/tgtx. Filings: https://lician.com/sec/tgtx
Not investment advice.